{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=15", "query": { "intervention": "Gleevec", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 351, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gleevec&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T18:44:40.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00062205", "title": "Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 40, "start_date": "2002-06", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2010-02-09", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062205" }, { "nct_id": "NCT01459757", "title": "Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "GIST" ], "interventions": [ { "name": "non-interventional", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2011-10", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 12, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01459757" }, { "nct_id": "NCT01391611", "title": "Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumor (GIST)" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kristen Ganjoo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2011-07", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 2, "location_summary": "Stanford, California • Boston, Massachusetts", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391611" }, { "nct_id": "NCT03007147", "title": "Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 352, "start_date": "2017-08-08", "completion_date": "2034-09-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 184, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03007147" }, { "nct_id": "NCT00573404", "title": "Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumor" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2007-07", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2011-11-16", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573404" }, { "nct_id": "NCT00290771", "title": "Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma Multiforme (GBM)" ], "interventions": [ { "name": "Imatinib tablets", "type": "DRUG" }, { "name": "Hydroxyurea capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2006-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2011-05-16", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290771" }, { "nct_id": "NCT00258271", "title": "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cladribine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-03", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2013-10-16", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258271" }, { "nct_id": "NCT00477269", "title": "Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Imatinib mesylate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2006-04", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-03-23", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 3, "location_summary": "Los Angeles, California • Newark, New Jersey • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477269" }, { "nct_id": "NCT00323791", "title": "Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2006-04", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2009-12-11", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323791" }, { "nct_id": "NCT00156286", "title": "Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Gleevec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2002-03", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2010-11-16", "last_synced_at": "2026-10-20T18:44:40.285Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156286" } ] }